Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma
暂无分享,去创建一个
Ka F To | J. Tong | K. To | A. Chan | R. W. Lung | K. Lo | D. Ng | Joanna H Tong | David C Ng | Shuk L Chau | Ken K So | Patrick P Leung | Tin L Lee | Raymond W Lung | Michael W Chan | Anthony W Chan | Kwok W Lo | M. Chan | S. Chau | Tin L. Lee | K. So | Patrick P. Leung
[1] K. To,et al. High resolution allelotype of microdissected primary nasopharyngeal carcinoma. , 2000, Cancer research.
[2] J. Kwong,et al. Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma , 2005, International journal of cancer.
[3] R. Erikson,et al. The polo-box-dependent induction of ectopic septal structures by a mammalian polo kinase, plk, in Saccharomyces cerevisiae. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[4] A. Baldini,et al. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer , 1998, Oncogene.
[5] C. Tseng,et al. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. , 1998, Endocrinology.
[6] Kwok Wai Lo,et al. Focus on nasopharyngeal carcinoma. , 2004, Cancer cell.
[7] Jonathan A. Cooper,et al. Disabled‐2 Colocalizes with the LDLR in Clathrin‐Coated Pits and Interacts with AP‐2 , 2001, Traffic.
[8] Xiang-Xi Xu,et al. Cell cycle-dependent phosphorylation of Disabled-2 by cdc2 , 2003, Oncogene.
[9] Elizabeth R. Smith,et al. Disabled-2 Exerts Its Tumor Suppressor Activity by Uncoupling c-Fos Expression and MAP Kinase Activation* , 2001, The Journal of Biological Chemistry.
[10] H. Friess,et al. Down-Regulation of DOC-2 in Colorectal Cancer Points to Its Role as a Tumor Suppressor in This Malignancy , 2002, Diseases of the colon and rectum.
[11] Yair Lotan,et al. Decreased DOC-2/DAB2 Expression in Urothelial Carcinoma of the Bladder , 2007, Clinical Cancer Research.
[12] J. Kwong,et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. , 2001, Cancer research.
[13] J. Kwong,et al. RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma , 2004, International journal of cancer.
[14] C. Tseng,et al. Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor. , 2005, Cancer research.
[15] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[16] A. Hui,et al. Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation , 1999, International journal of cancer.
[17] Y. Jiang,et al. The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin , 2008, Oncogene.
[18] C. Tseng,et al. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. , 2005, Cancer research.
[19] C. Tseng,et al. The Mechanism of Growth-inhibitory Effect of DOC-2/DAB2 in Prostate Cancer , 2002, The Journal of Biological Chemistry.
[20] Jonathan A. Cooper,et al. Myosin VI Binds to and Localises with Dab2, Potentially Linking Receptor‐Mediated Endocytosis and the Actin Cytoskeleton , 2002, Traffic.
[21] Yusuke Nakamura,et al. Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma , 2007, Genes, chromosomes & cancer.
[22] J. Hsieh,et al. The Inhibitory Role of DOC-2/DAB2 in Growth Factor Receptor-mediated Signal Cascade , 2001, The Journal of Biological Chemistry.
[23] J. Hsieh,et al. Characterization of a Novel Negative Regulator (DOC-2/DAB2) of c-Src in Normal Prostatic Epithelium and Cancer* , 2003, The Journal of Biological Chemistry.
[24] Elizabeth R. Smith,et al. c‐fos elimination compensates for disabled‐2 requirement in mouse extraembryonic endoderm development , 2009, Developmental dynamics : an official publication of the American Association of Anatomists.
[25] F. Dong,et al. Structure, sequence, and promoter analysis of human disabled-2 gene (DAB2). , 2000, Genomics.
[26] M. Fukayama,et al. Epstein–Barr virus and gastric carcinoma: virus–host interactions leading to carcinoma , 2008, Cancer science.
[27] Siddhartha Datta Gupta,et al. Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. , 2006, World journal of gastroenterology.
[28] Leila Mohammadi,et al. BMC Cancer , 2001 .
[29] R. Berkowitz,et al. DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases , 1998, Oncogene.
[30] J. Herman,et al. GATA-4 and GATA-5 Transcription Factor Genes and Potential Downstream Antitumor Target Genes Are Epigenetically Silenced in Colorectal and Gastric Cancer , 2003, Molecular and Cellular Biology.
[31] Xiang-Xi Xu,et al. Disabled-2 inactivation is an early step in ovarian tumorigenicity , 1999, Oncogene.
[32] P. Howe,et al. Disabled-2 (Dab2) Mediates Transforming Growth Factor β (TGFβ)-stimulated Fibronectin Synthesis through TGFβ-activated Kinase 1 and Activation of the JNK Pathway* , 2005, Journal of Biological Chemistry.
[33] Qian Tao,et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. , 2009, Gastroenterology.
[34] C. Rock,et al. Cloning of a Novel Phosphoprotein Regulated by Colony-stimulating Factor 1 Shares a Domain with the Drosophiladisabled Gene Product (*) , 1995, The Journal of Biological Chemistry.
[35] Louis V. DePaolo,et al. Pre-Application Technical Assistance Webinar for NICHD Program Announcements for Vulvodynia - Systematic Epidemiologic, Etiologic, or Therapeutic Studies (NOT-HD-11-015) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institutes of Health (NIH) , 2011 .
[36] L. You,et al. Nasopharyngeal carcinoma—Review of the molecular mechanisms of tumorigenesis , 2008, Head & neck.
[37] R. Ralhan,et al. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer , 2007, Breast Cancer Research and Treatment.
[38] A. Hui,et al. Molecular cytogenetic characterization of nasopharyngeal carcinoma cell lines and xenografts by comparative genomic hybridization and spectral karyotyping. , 2003, Cancer genetics and cytogenetics.
[39] Ying Liang,et al. Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. , 2006, Cancer research.
[40] P. Howe,et al. Disabled-2 (Dab2) Is Required for Transforming Growth Factor β-induced Epithelial to Mesenchymal Transition (EMT)* , 2005, Journal of Biological Chemistry.
[41] Jonathan A. Cooper,et al. Regulation of the Wnt signaling pathway by disabled‐2 (Dab2) , 2003, The EMBO journal.
[42] J. Kwong,et al. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] A. Hui,et al. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma , 2003, Molecular carcinogenesis.
[44] S. Tsao,et al. Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. , 2002, Biochimica et biophysica acta.
[45] Xiang-Xi Xu,et al. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2 , 1998, Oncogene.
[46] Xiang Xu,et al. Erratum: Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product (Journal of Biological Chemistry (1995) 270 (14184-14191)) , 1996 .